European Federation of Pharmaceutical Industries and Associations (EFPIA)
Warning! As of 20 September 2021, the EU lobby register has changed format. Temporarily, the register is no longer providing daily data updates of all lobby data which means that the figures on LobbyFacts cannot currently be kept up-to-date. If, for example, you see a company, trade association, or lobby consultancy with "no figure available" for EU lobby costs, open the data card, and click the link to the EU lobby register where you will find the updated registration including EU lobby costs declaration. Regretably, under the lobby register format, NGOs and think tanks are no longer required to provide a figure for EU lobby costs. We will update LobbyFacts with the new data as soon as possible.
Lobbying costs:
WARNING: As this organisation lists one or more EP accredited lobbyists, it is highly improbable that its lobbying costs are lower than €10,000.
WARNING: The lobbying costs declared by this organisation are extraordinarily high and may therefore have been over-declared.
5,250,000€ - 5,499,999€
Lobbyists declared: 9 FTE (25)
WARNING: The number of full time equivalent lobbyists declared by this organisation are extraordinarily high and may therefore have been over-declared.
Lobbyists with EP accreditation: 11
Meetings with European Commission: 102
Lobbying costs over the years:
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Registration on EU Transparency Register
Website
Goals / Remit
EFPIA represents the biopharmaceutical industry operating in Europe. Through its direct membership of 36 national associations, 39 leading pharmaceutical companies, and a growing number of small and medium-sized enterprises (SMEs), EFPIA’s mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy. Our vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and
better outcomes for patients.
EFPIA’s activities extend to all matters of common interest to its members. In particular, it aims to foster an environment that encourages pharmaceutical research and development, manufacture in compliance with high-quality standards, intellectual property protection and the introduction of regulatory requirements to allow patients rapid access to medicinal products.
Issues
Any health or pharmaceutical policy stemming from the European institutions, such as life sciences strategy, industrial policy, European Semester, Horizon Europe Research Programme, HTA policy, IP policy, Pharmaceutical Strategy, One Health Approach to tackle AMR, pharmaceutical, orphan and paediatrics legislation, COVID-19 outbreak measures. EFPIA also follows ongoing trade negotiations and legislative files when relevant to the innovative pharmaceutical industry (such as Green Deal, Water Framework Directive, Welfare of animals in scientific testing etc).
Address
8 Rue Mil Neuf Cents
Luxembourg L-2157
Luxembourg
Tel: 32 26262555
Belgium office:
Rue du Trône 108
Brussels 1050,
Belgium
Tel: 32 26262555